Related Experiment Video
Updated: Jan 11, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Efficacy of secukinumab in pediatric patients with moderate to severe plaque psoriasis: A randomized study
Yuping Zhang1,2, Xiji Lu3, Ying Zhou1
1Department of dermatology, Zhongshan City People's Hospital, Zhongshan, China.
Insights
Secukinumab effectively treats moderate to severe pediatric psoriasis, significantly improving skin clearance and quality of life compared to traditional therapies. This interleukin-17A inhibitor shows promise for young patients in China.
Area of Science:
- Dermatology
- Immunology
- Pediatric Medicine
Background:
- Secukinumab, an IL-17A inhibitor, is approved for pediatric psoriasis in the EU and US, but not China.
- Psoriasis affects children, impacting their quality of life.
- Evaluating novel biologic therapies for pediatric psoriasis is crucial.
Purpose of the Study:
- To assess the clinical efficacy and safety of secukinumab in Chinese pediatric patients with moderate to severe plaque psoriasis.
- To compare secukinumab with conventional non-biologic therapy.
Main Methods:
- A randomized, single-center study involving 33 pediatric patients (6-17 years).
- Treatment arms included secukinumab and conventional non-biologic therapy.
- Primary outcomes: BSA, PASI 75/90/100, IGA 0/1, DLQI, and adverse events.
Main Results:
- Secukinumab significantly reduced BSA and PASI scores versus conventional therapy.
- Higher rates of IGA 0/1, DLQI improvement, and PASI 90 response observed with secukinumab.
- No significant dose-dependent differences between 150mg and 300mg secukinumab.
Conclusions:
- Secukinumab demonstrates therapeutic efficacy and safety in Chinese pediatric patients with moderate to severe plaque psoriasis.
- The findings support secukinumab as a potential treatment option for this population.
- Further research may explore long-term outcomes and comparative effectiveness.
Background:
Secukinumab, an IL-17A inhibitor, is approved for moderate to severe psoriasis in children over 6 years old in the European Union and the United States, but not yet in China. This study evaluates the clinical efficacy and safety of secukinumab in Chinese pediatric patients with moderate to severe plaque psoriasis.
Methods:
A randomized, single-center study was conducted with 33 patients aged 6 to 17 years. Patients were treated with either secukinumab or conventional non-biologic therapy. The primary outcomes assessed included body surface area (BSA), Psoriasis Area and Severity Index (PASI) 75/90/100 responses, Investigator's Global Assessment 0/1 (IGA 0/1), Dermatology Life Quality Index, and the incidence of adverse events (AEs).
Results:
Compared to the conventional treatment group, the secukinumab group demonstrated significant reductions in BSA and PASI scores, as well as higher rates of IGA 0/1, Dermatology Life Quality Index improvement, and PASI 90 response. Subgroup analysis of the secukinumab group indicated lower BSA and PASI scores in patients without prior treatment compared to those with prior treatment. No significant differences were observed between the 150 mg and 300 mg dose groups regarding BSA and PASI decrease rates.
Conclusion:
Secukinumab demonstrates therapeutic efficacy and safety in the treatment of moderate to severe plaque psoriasis in pediatric and adolescent patients, suggesting its potential as a treatment option for this population.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption